Brief: Medincell Announces Three New Products Entering Regulatory Development
02/02/2021 18:29
Feb 2 (Reuters) - MEDINCELL SA MEDCL.PA :
* MEDINCELL ANNOUNCES THREE NEW PRODUCTS ENTERING REGULATORY
DEVELOPMENT
* IN VIVO STUDIES DEMONSTRATED FEASIBILITY OF THREE NEW
LONG-ACTING INJECTABLE TREATMENTS: MDC-GRT (ORGAN TRANSPLANT),
MDC-KPT (PAIN / ANIMAL HEALTH) AND MDC-TTG (COVID-19)
Source text for Eikon: ID:
Further company coverage: MEDCL.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; 48 58 7696600;))